Cargando…
MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways
While MDM2 inhibitors hold great promise as cancer therapeutics, drug resistance will likely limit their efficacy as single agents. To identify drug combinations that might circumvent resistance, we screened for agents that could synergize with MDM2 inhibition in the suppression of cell viability. W...
Autores principales: | Saiki, Anne Y., Caenepeel, Sean, Yu, Dongyin, Lofgren, Julie A., Osgood, Tao, Robertson, Rebecca, Canon, Jude, Su, Cheng, Jones, Adrie, Zhao, Xiaoning, Deshpande, Chetan, Payton, Marc, Ledell, Jebediah, Hughes, Paul E., Oliner, Jonathan D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039142/ https://www.ncbi.nlm.nih.gov/pubmed/24810962 |
Ejemplares similares
-
Identifying the determinants of response to MDM2 inhibition
por: Saiki, Anne Y., et al.
Publicado: (2015) -
Tumorigenesis promotes Mdm4-S overexpression
por: Pant, Vinod, et al.
Publicado: (2017) -
Inhibition of Mdmx (Mdm4) in vivo induces anti-obesity effects
por: Kon, Ning, et al.
Publicado: (2018) -
Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors
por: Li, Yizhu, et al.
Publicado: (2015) -
Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies
por: Müller, Fabian, et al.
Publicado: (2017)